Forty-two patients undergoing minimally invasive sacroiliac joint fusion (MISJF) were randomized to receive intra-articular infiltration with bupivacaine 0.50% (n=22) or placebo (NaCl 0.9%) (n=19). The primary outcome was postoperative pain scores assessed using the visual analog scale (VAS) over 48 hours. Secondary outcomes included opioid consumption, patient satisfaction, recovery scores, adverse events, and length of hospital stay. Outcomes were measured at several intervals up to 48 hours postoperatively. Overall, the results revealed no significant difference in pain scores (p=0.68) or secondary outcomes, including opioid consumption (p=0.81), between the bupivacaine and placebo groups. The study concluded that intra-articular infiltration with bupivacaine does not improve postoperative pain management or reduce opioid use and should not be routinely employed in MISJF.